Tag Archives: Sorrento Therapeutics

H.C. Wainwright Reaffirms Their Buy Rating on Sorrento Therapeutics

In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Sorrento Therapeutics (NASDAQ: SRNE), with a price target of $40. The company’s shares closed on Friday at $7.45. Selvaraju commented: “We draw investors’ attention to

Sorrento Therapeutics Gets a Buy Rating from H.C. Wainwright

H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Sorrento Therapeutics (NASDAQ: SRNE) today and set a price target of $40. The company’s shares closed on Friday at $7.60. Selvaraju wrote: “We reiterate our Buy rating and 12-month target

Oppenheimer Keeps a Buy Rating on Sorrento Therapeutics

Oppenheimer analyst Mark Breidenbach maintained a Buy rating on Sorrento Therapeutics (NASDAQ: SRNE) today and set a price target of $10. The company’s shares closed yesterday at $7.35. Breidenbach wrote: “Thursday, Sorrento reported 1Q results and we recently went on

Analysts Offer Insights on Healthcare Companies: Sorrento Therapeutics (NASDAQ: SRNE) and IntelGenx Technologies (Other OTC: IGXT)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Sorrento Therapeutics (NASDAQ: SRNE) and IntelGenx Technologies (Other OTC: IGXT) with bullish sentiments. Sorrento Therapeutics (NASDAQ: SRNE) H.C. Wainwright analyst Ram Selvaraju

Analysts’ Top Healthcare Picks: SRNE, MDCO

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Sorrento Therapeutics (NASDAQ: SRNE), Medicines Co (NASDAQ: MDCO) and AVEO Pharma (NASDAQ: AVEO) with bullish sentiments. Sorrento Therapeutics (NASDAQ: SRNE) Oppenheimer analyst

Sorrento Therapeutics Receives a Buy from Oppenheimer

In a report released today, Mark Breidenbach from Oppenheimer maintained a Buy rating on Sorrento Therapeutics (NASDAQ: SRNE), with a price target of $11. The company’s shares opened today at $7.80. Breidenbach wrote: “Last Friday, Sorrento reported 4Q17 earnings and